Objective: To study interactions between first-trimester exposure to antidepressant drugs (ADDs) and antiepileptic drugs (AEDs), and a history of clinical depression and/or anxiety, on pregnancy outcomes and seizure control in pregnant women with epilepsy (WWE). Methods: We examined data from the Australian Pregnancy Register of Antiepileptic Drugs in Pregnancy, collected from 1999 to 2016. The register is an observational, prospective database, from which this study retrospectively analyzed a cohort. Among the AED-exposed outcomes, comparisons were made among 3 exposure groups: (1) pregnancy outcomes with first-trimester exposure to ADDs; (2) outcomes with mothers diagnosed with depression and/or anxiety but who were not medicated with an ADD; and (3) those with mothers who were not diagnosed with depression and/or anxiety and were not medicating with ADD. Prevalence data was analyzed using Fisher's exact test. Results: A total of 2124 pregnancy outcomes were included in the analysis; 1954 outcomes were exposed to AEDs in utero, whereas 170 were unexposed. Within the group of WWE taking AEDs, there was no significant difference in the prevalence of malformations in infants who were additionally exposed to ADDs (10.2%, 95% confidence interval [CI] 3.9-16.6), compared to individuals in the non-ADD-medicated depression and/or anxiety group (7.7%, 95% CI 1.2-14.2), or those without depression or anxiety (6.9%, 95% CI 5.7-8.1; P = 0.45). The malformation rates in pregnancy outcomes unexposed to AEDs were also similar in the above groups (P = 0.27). In WWE medicated with AEDs and ADDs, the frequency of convulsive seizures (P = 0.78), or nonconvulsive seizures (P = 0.45) throughout pregnancy, did not differ across comparative groups. Significance: Co-medicating with ADDs in WWE taking AEDs does not appear to confer a significant added teratogenic risk, and it does not affect seizure control.
| INTRODUCTION
Women with epilepsy (WWE) comprise up to 0.7% of all pregnancies.
1 Although a few WWE can discontinue antiepileptic drugs (AEDs) prior to conception, most will require continued use during pregnancy to achieve seizure control. 2 It is widely accepted that first-trimester exposure to AEDs increases the risk of congenital malformations (CMs) from the background risk. 3 Psychiatric conditions are commonly comorbid with epilepsy, affecting up to a third of patients. 4 Depression is the most common of these, with many population-based studies reporting a prevalence of more than 20%. 5 Antidepressant drug (ADD) treatment in pregnant women has been steadily increasing over the last 20 years, despite their use being questioned as potentially increasing the risk of CMs. 6, 7 Despite this, the combined fetal risk of medicating with both AEDs and ADDs in WWE has not been addressed in the scientific literature. Furthermore, there has been a longstanding concern among clinicians that certain ADDs may decrease the seizure threshold, where approximately half of WWE have at least one seizure during pregnancy. [8] [9] [10] [11] Whether ADD use during pregnancy could be associated with worse seizure control, is also an important clinical question that has not been addressed in previous studies. Therefore, we designed this study to investigate the use of ADD treatment during pregnancy, utilizing data from the Australian Pregnancy Register (APR) of Antiepileptic Drugs.
| METHODS
The APR of Antiepileptic Drugs in Pregnancy has been prospectively collecting observational data concerning the pregnancies and fetal outcomes in WWE since 1999. 12 The APR is a voluntary, Australia-wide, telephone interviewbased register. The register requires written informed consent and has ethics committee approval from the Melbourne Health Human Research and Ethics Committee. For this study, a retrospective analysis comparing in WWE the rate of CMs and the occurrence of seizures, and the relationship of these to co-medication with ADD and a history of depression, was performed on women enrolled from the register's inception in 1999 until 2016. The register also enrolls women who are taking AEDs for reasons other than epilepsy, but these women who represent approximately 1% of participants were excluded in this analysis. During the period of participation of WWE in the Register, 4 interviews were conducted: (1) on recruitment (usually in the first or second trimester); (2) 7 months of pregnancy; (3) within the postnatal month; and (4) at the end of the postnatal year. Details regarding the pregnancy outcomes were obtained in the third interview, and repeated, in case of any changes, in the fourth interview. CMs were classified per the Birth Defects Registry of Victoria. 13 Women were asked for occurrence of seizures at each of the interviews; however, for the purposes of effective comparison, only binary seizure outcomes were analyzed (ie, whether seizures occurred or did not occur during pregnancy). Because seizures were self-reported, there was no reliable method to discern between true epileptic seizures and nonepileptic events. After excluding women who did not have epilepsy, 2 exposure types were first determined: WWE who were medicating with at least one AED and WWE who were not under medical treatment for their epilepsy at the time they became pregnant. These 2 groups were further subcategorized based on 3 additional exposure types in each of the AED treated and AED untreated groups: (1) mothers treated with ADDs; (2) mothers with depression and/or anxiety but were not medicated with ADDs; and (3) mothers without depression and/or anxiety who were not medicated with ADDs.
The APR routinely asks women about whether they have comorbid medical and psychiatric illnesses, including depression, and for all medications taken in addition to AEDs. Dosage information was recorded if volunteered, but because this information was incomplete in many women, this was excluded in our analyses.
There are many reasons for medicating with ADDs. Although this study centers around depression and anxiety, we recognize that obsessive-compulsive disorder, pain, and migraines can be other potential reasons for medication with ADDs.
14 For the purposes of effective comparison, women must have had a diagnosis of depression and/or anxiety to be considered. Five women had a diagnosis of bipolar disorder and were on ADDs; these women were also included. 
| Statistical methods
Statistical analyses were performed with STATA 12 (StataCorp, College Station, Texas). Characteristics of the study population was expressed as counts (with %) and medians (with interquartile ranges). Comparisons between groups were performed using the Kruskal-Wallis one-way analysis of variance for continuous data, and the Fisher's exact test for categorical data. A two-tailed P value of <0.05 was considered statistically significant on all tests performed.
| RESULTS
When the data for this study was analyzed, 2081 WWE had completed their pregnancies on the APR, including 43 twin pregnancies, resulting in a total of 2124 pregnancy outcomes. A total of 1592 women (76.5%) were between the ages of 21 and 34, and 449 (21.6%) were over the age of 35 (Table 1) . A total of 1647 women (79.1%) were employed at enrollment, and 1653 (79.4%) belonged to households with an income >$50 000.
A total of 1912 women (91.9%) were medicating with at least one AED, whereas 169 (8.1%) were not medically treated for their epilepsy at the time they became pregnant. The 1371 women (71.7%) on AED therapy required only one AED, but 541 (28.3%) were taking 2 or more AEDs. Among the AED-medicated women, 203 (10.6%) reported tobacco use during pregnancy, 315 (16.5%) consumed alcohol, and 1821 (95.2%) were supplementing with folic acid prior to conception and in the first trimester. Among the WWE who were not treated with an AED, 10 (5.9%) reported tobacco use throughout pregnancy, 32 (18.9%) consumed alcohol, and 150 (88.8%) were supplementing with folic acid.
One hundred fifty-nine women (7.6%) reported clinical depression and/or anxiety, of which, 94 (59.1%) were medicating with an ADD (Table 2) . Fifty-seven women (65.5%) medicated with an ADD were on SSRI monotherapy, 13 (14.9%) were on SNRI monotherapy, and 5 (5.7%) were on ADD polytherapy or medicating with an ADD combined with an antipsychotic (Table 5) . A diagnosis of depression and/or anxiety (both treated and untreated with ADDs) did not affect the rates of cigarette smoking and alcohol use (Table 1) . In women treated with AEDs, those with untreated depression and/or anxiety were twice as likely (11.3%) to not use folic acid supplementation as those who were taking an ADD (4.6%).
In pregnancy outcomes exposed to AEDs, women who were additionally exposed to ADDs had a CM rate (10.2%, 95% confidence interval [CI] 3.9-16.6) that was comparable to that of the control groups (7.7%, 95% CI 1.2-14.2 and 6.9%, 95% CI 5.7-8.1; Table 2 ). Of pregnancy outcomes in women who were not exposed to AEDs but exposed to ADDs, one (14.3%, 95% CI 0-40.2) CM was seen, compared with 0% and 2.5% (95% CI 0.1-4.9) in the comparison groups (Table 3) . Live births without defects and the baby's median birth weights were statistically similar across the comparison groups, for both AED-exposed and AEDunexposed women. Spontaneous abortions and still births were not statistically analyzed due to insufficient numbers in the depressed and/or anxious group.
The malformation rate in pregnancy outcomes with mothers who did not have depression and/or anxiety was almost 3 times (6.9%, 95% CI 5.7-8.1) greater in those exposed to AEDs than in those unexposed (2.5%, 95% CI 0.1-4.9; P = 0.02). Similarly, for pregnancy outcomes in women without exposure to depression and/or anxiety but who had AED treatment, there were 55 (3.1%) spontaneous abortions, compared to zero in the same exposure group but without AED treatment (P = 0.01).
Overall, medicating with ADDs in WWE, who were both treated and untreated with AEDs, was not associated with significantly different frequencies of convulsive or nonconvulsive seizures (Table 4) . ADD-and AED-treated women had a significantly greater frequency of nonconvulsive seizures than in the comparison groups at only one time point: 7 months to delivery. The number of women who had at least one seizure at each of the telephone interview time intervals was similar for both AED-treated and AED-untreated women, across all comparison groups (Table 4) . Four (4.6%) and 9 (10.3%) women who were treated with AEDs and ADDs, respectively, had sustained convulsive and nonconvulsive seizures throughout pregnancy.
Specific ADDs were not associated with any adverse pregnancy outcomes and birth weight (Table 5) . Sertraline was the most popular SSRI (44%) and the most popular ADD overall, with 25 WWE (28.7%) WWE taking this ADD during their pregnancy. Three CMs occurred in women taking sertraline, 4 with citalopram and escitalopram, respectively, and 2 with other atypical ADDs. The 
| DISCUSSION
Our findings from the APR suggest that among WWE, including those treated and untreated with AEDs, having depression and/or anxiety with or without treatment with ADDs does not appear to increase teratogenicity for the fetus, or affect the occurrence of seizures during pregnancy.
To the best of our knowledge, this is the first study to evaluate the teratogenicity of ADDs in WWE, and the association with seizure control, 2 clinically important issues. The teratogenicity of prenatal AED exposure is widely known. Exposure carries an inherent risk for major CMs of around 4%-9%, compared with the background risk of 1%-2%. [15] [16] [17] [18] Of the AEDs, valproic acid is the most well-documented teratogen. A meta-analysis that collated 59 studies concerning 65 533 WWE, found an overall risk of 10.73%
for major congenital malformations with valproic acid use. 2 These findings were consistent with results of our study showing an increased malformation rate of almost 3-fold in pregnancies exposed to AEDs, compared to pregnancies not exposed to AEDs. On the other hand, the literature on malformation risks of ADDs has been more equivocal. SSRIs are the most common class of ADDs prescribed in developed countries such as Australia, with a prevalence of 80%. 19 No previous study has examined the risk of taking ADDs in WWE, or the interaction with AEDs on this risk. This study did not find a significantly increased risk of CMs by co-medicating with ADDs and AEDs concurrently. Likewise, there was no significant increased risk of the women having a history of depression and/or anxiety. There was a small absolute increase in the incidence of CMs in women taking ADDs and AEDs compared to individuals in the non-ADD-medicated depression and/or anxiety group and to those without depression or anxiety who were also taking AEDs. It is therefore possible that a small increased risk was missed due to lack of power, and this argues for the importance of future large-scale studies examining this important issue. In addition, this study had only three women with pregnancy outcomes who were exposed to ADDs but not AEDs, and thus a statistically relevant observation about the effects of ADDs alone is not possible.
Despite a longstanding concern among clinicians that prescribing ADDs for people with epilepsy may adversely affect seizure control, evidence indicates that the risk of seizures from medicating with SSRIs is low (0.0%-0.4%), and not clearly greater than the incidence of first seizures in the general population (0.07%-0.09%). 8, 34 Most women in developed countries with depression are treated with an SSRI, as was the experience in this study population. WWE taking ADDs only had statistically more nonconvulsive seizures than those not taking ADDs during the last 2 months of pregnancy. This could be because during this time 5 women belonging to the atypical ADD group, which includes TCAs, had nonconvulsive seizures. Furthermore, the seizure occurrence in this time interval was minimal for the other classes of ADDs. TCAs taken at therapeutic doses are thought to be associated with a higher risk (0.4% to 1%-2%) of precipitating seizures. 34 In one study, poor seizure control was found to be a risk factor for depression and anxiety. 35 Unfortunately, this study did not assess for a proportional relationship. Our study not only compared women exposed to ADDs to those without the relevant psychiatric illness, but also to those with nonmedicated depression and/or anxiety. Symptomatic depression has risks to the fetus including low birth weight, small for gestational age, preterm delivery, fetal irritability, less activity and attentiveness, and fewer facial expressions as well as maternal risks of self-injury, suicide, inadequate self-care, and poor compliance with prenatal care. [36] [37] [38] [39] Assessing the direct effect of depression and/or anxiety is difficult, as shown by the relative scantiness of data assessing for the teratogenicity of ADDs. There are many reasons for depressed or anxious women not using ADDs. Women could be avoiding taking ADDs due to potential teratogenic properties, have milder affective symptoms, or could be utilizing nonpharmacologic management strategies. However, like other studies examining the teratogenicity of ADDs, untreated depression in this study was not associated with CMs. 21, 23, 28 This study also found no association of a history of depression and/or anxiety with birth weight or maternal seizure control. This study was not without limitations. The telephone questionnaire used in the APR was not primarily designed to collect detailed information regarding psychiatric comorbidities, and neither were medical records routinely requested. As such, if women responded positively to having depression and/or anxiety, these binary data were recorded and no further questions were asked regarding the nature of the illness, including how it was diagnosed or the severity. As such, women with severe symptoms could have been compared to those with milder symptoms. Of 2081 women enrolled in the study, only 94 (4.5%) were on ADDs, which is comparable to one Australian study (4.6%) looking at antidepressant use in pregnancy but is approximately half of the rate found in one large observational study involving over one million pregnant women in the United States. 19, 40 This discrepancy could be explained by varying prescription standards between countries or, as one study found, WWE are less likely to be prescribed ADDs when compared to pregnant women without epilepsy. 35 Similarly, only 3.1% of pregnant women had depression listed on their admission record in one study (compared with 7.6% in our study), and they also found 80% of women were dispensed an ADD without a relevant psychiatric comorbidity listed. 40 The difference in the prevalence of depression and/or anxiety could be explained by women in our study overreporting because they were self-diagnosing based on symptoms or unsure of a diagnosis. Furthermore, data on ADD dosage and changes in dosage throughout pregnancy were incomplete. Although this study was concerned mainly with first-trimester exposure of ADDs, changing dosages during pregnancy could have led to medical interpretations regarding efficacy of treatment and severity of the psychiatric illness. One study identified a significant relationship between CMs and congenital heart defects only when paroxetine was taken at dosages exceeding 25 mg/day. 21 As such, defining dosage relationships in this study was not possible.
| CONCLUSION
The data reported here represent the first to specifically address the risk for CMs and seizures from co-medicating with ADDs in WWE. Although this study was limited by statistical power, the results indicate that taking AEDs does not appear to confer major teratogenic risk and it does not it affect seizure control. These data should be helpful for clinicians who are treating and counseling WWE who have depression and/or anxiety, for which an ADD may be indicated. Future research addressing these clinically important questions with a larger cohort of individuals is warranted to confirm these findings. This would require a collaborative effort from several ongoing prospective databaselinked studies and population studies.
